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EDITORIAL COMMENT
“Watchful Waiting”
After Thrombolysis
It’s Time for a Re-Evaluation*
William W. O’Neill, MD, FACC
Royal Oak, Michigan
On December 23, 2002, a colleague contacted me for a
patient referral. The patient was a 43-year-old male who
had presented to an outlying hospital the night before with
an evolving inferior ST-elevation myocardial infarction
(STEMI). He presented within 2 h of symptom onset and
was treated with thrombolytic therapy. Clinically, he
promptly reperfused (ST resolution, complete chest-pain
relief), and he had only a mild elevation of cardiac enzymes.
My colleague and I discussed treatment options. We rea-
soned that the infarct had largely been aborted and a
persistent high-grade obstructive lesion was likely. For this
reason, the patient was transferred that day. At catheteriza-
tion, we found a subtotal occlusion of the distal right
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coronary artery with TIMI (Thrombolysis In Myocardial
Infarction) grade III flow and minimal posterobasal hypo-
kinesis. A 3.5-mm stent was inserted into the right coronary
artery with an excellent result. The patient was observed
overnight and discharged the next day (Christmas Eve).
The patient, his wife and his children were together for this
holiday largely because of the nearly miraculous power of
timely reperfusion and revascularization therapy.
While this was a clinically heartwarming episode, this
admission created a bureaucratic morass. I received a curt
letter from the patient’s insurance carrier denying physician
and hospital payment because of unnecessary care. Ulti-
mately, after numerous phone calls and letters, payment was
rendered. The reason for this controversy was that a stress
test for inducible ischemia had not been performed after
thrombolytic therapy, as their payment algorithms man-
dated. These algorithms were based on published guide-
lines.
Currently, either primary percutaneous coronary inter-
vention (PCI) or intravenous thrombolytic therapy are
considered effective initial treatments for STEMI and have
Class I (American College of Cardiology/American Heart
Association [ACC/AHA]) or Class A (European Society of
Cardiology) recommendations (1,2). In the U.S., recent
surveys (3,4) demonstrate that only 15% of ST-elevation
patients are treated with primary PCI, whereas the majority
are treated with thrombolytics. Thus, the use and timing of
PCI after thrombolytic therapy remain important practice
issues. The ACC/AHA guidelines suggest that immediate
post-thrombolysis PCI is ineffective or harmful (Class III).
These guidelines also suggest that use of PCI hours to days
(48 h) after successful thrombolysis is controversial (Class
II). Only rescue PCI is considered a Class I indication for
use of PCI after thrombolytics. Given the restrictive nature
of these recommendations, it is problematic that in the U.S.
71% of patients have catheterization and 58% have revas-
cularization after thrombolytic use (5). On a day-to-day
basis clinicians are faced with the ethical, financial, and
medicolegal ramifications of recommendations based on
randomized trials that are more than a decade old.
It is of interest, then, that Gibson et al. (6) describe the
impact of reinfarction in 20,101 thrombolytic-treated pa-
tients in this issue of the Journal. Gibson et al. (6) reports
that reinfarction occurred in 4.2% of patients treated in the
TIMI 4, 9, 10B, and 17 trials. Although reinfarction was
relatively infrequent, it was associated with a significantly
greater 30-day and two-year mortality. In fact, when revas-
cularization was not used, a 24% hospital mortality occurred
for patients suffering reinfarction. Overall mortality ap-
peared to be significantly decreased (6.75% to 2.76%, p 
0.0001) when PCI was used. Risk of reinfarction was also
lower when PCI or coronary artery bypass graft (CABG)
was used. Reinfarction tended to occur early, a mean of 2.2
days after admission. Kaplan-Meier curves demonstrate that
the highest risk of death after reinfarction was during the
index admission. A highly predictive model to predict
reinfarction risk, based on clinical variables, could not be
generated. There are significant limitations to this pooled
analysis. Different thrombolytic agents were used in each
trial. Definitions of “reinfarction” varied, and in one trial
(TIMI 10B) the definition was not centrally adjudicated. In
addition, whether PCI was prompted by reinfarction or was
the cause of reinfarction could not be retrospectively deter-
mined in some patients. Despite these limitations, the
detailed analysis of PCI use after thrombolytic therapy in a
large contemporaneous practice makes these study results
important for discussion. The main findings of this report
are that recurrent infarction after thrombolytic therapy
occurs early, is unpredictable, is associated with a high
mortality, and may be reduced by performance of PCI or
CABG during the index admission.
The patient anecdote presented here and the report by
Gibson point out major gaps in our current understanding
of the proper role of revascularization after thrombolytic
therapy. Logistics and patient convenience favor early cath-
eterization and revascularization. The Gibson et al. (6)
report furthermore suggests a major safety benefit with PCI
or CABG after thrombolysis. Clinicians in the U.S. recog-
nize these advantages and perform catheterization and PCI
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in the majority of patients. Unfortunately, the initial ran-
domized trials of routine catheterization and angioplasty
suggested a deleterious effect with this approach (7–11).
These trials tested the routine strategy of conservative care
(also known as “watchful waiting”) compared with imme-
diate catheterization and angioplasty. No benefit, and a
disturbing trend toward high mortality, occurred with the
aggressive approach (12). Although these trials are more
than 15 years old, they still drive treatment (and reimburse-
ment) algorithms.
A number of trials of interventional therapy of acute
coronary syndromes (ACS) and post-lytic PCI have been
performed (Table 1) (13–18). Ruptured or fissured coronary
plaques with superimposed intraluminal thrombus are be-
lieved to cause both STEMI and ACS/NSTEMI. Timely,
successful thrombolysis removes the thrombotic occlusion
and leaves coronary architecture similar to that found in
ACS/NSTEMI. It is difficult to understand why random-
ized trials of post-lytic PCI appear to give such discordant
results when used after successful thrombolytic therapy
compared with ACS (7–11,19–21). Can these discordant
results be reconciled?
First, it must be understood that the original randomized
post-thrombolytic trials were done in an early era of
angioplasty. Heparin dosage was excessive; large bore arte-
rial and venous sheaths were employed. The deleterious
local harm caused by thrombolytic therapy was not under-
stood (19). Furthermore, the role of thrombin-mediated
platelet activation was unknown at that time. Intervention-
alists were operating in a hostile environment with primitive
equipment. Today—armed with low-profile guiding cathe-
ters, superb X-ray equipment, potent antiplatelet agents,
thrombin inhibitors, and especially, flexible, deliverable
stents—angioplasty results have dramatically improved (22).
The more recent ACS trials have routinely used newer
generation stents and glycoprotein receptor blockers. The
TIMI-TACTICS (Treat Angina with Aggrastat and de-
termine the Cost of Therapy with Invasive or Conservative
Strategy) investigators have demonstrated that with these
modern techniques, the early hazard of PCI in ACS has
been largely eliminated (14). In addition, the use of throm-
bectomy devices (23) and distal protection devices (24) may
further decrease the risk of reinfarction due to distal
embolization. Finally, as Yarlagadda and Boden (25) have
suggested, pharmacologic interventions with statins (26)
and thienopyridines (27) have further improved the out-
comes after PCI in ACS.
There is no doubt that thrombolytic therapy will remain
a widely applied treatment of STEMI worldwide. What
lessons can be gleaned from the modern ACS trials and the
report of Gibson et al. (6)? We must recognize that
reinfarction after successful thrombolytic therapy occurs
early, is unpredictable, and has lethal consequences if PCI or
CABG is not performed. Thus “watchful waiting” means
exactly that. Clinicians must carefully watch for signs of
recurrent ischemia or reinfarction. They must also have a
well-organized triage and transfer program set up so that
PCI or CABG can be promptly performed. If patients
develop recurrent ischemia, further attempts at medical
stabilization are pointless because, as Gibson notes, patients
have a one in four chance of dying unless PCI or CABG is
performed.
The expanded use of PCI beyond rescue PCI or for
recurrent ischemia is not currently supported by the ran-
domized trials. Gibson has suggested, and I strongly concur,
that re-evaluation of the strategy of routine catheterization
and PCI after thrombolytic therapy is warranted. This
re-evaluation would incorporate advances in pharmacother-
apy and employ modern interventional techniques and
clinical risk stratification. It is likely that such a trial would
have outcomes similar to those of the modern ACS trials.
Until these data are available, clinicians will be left with
conflicting and outdated trial data with which to make
crucial decisions about post-thrombolytic care.
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Table 1. Interventional Therapy Versus Conservative Care*
Intervention
Intervention Compared to Conservative Care
Better Same Worse
ACS/NSTEMI MATE (13) TIMI IIIB (17) VANQUISH (18)
TIMI TACTICS (14)
FRISC II (15)
RITA 3 (16)
Post-lytic PCI DANAMI I (20) PACT (21) TAMI I (7)
TIMI IIA (8)
ECSG (9)
Barbash et al. (11)
SWIFT (10)
SAMI (19)
*All patients had inducible ischemia prior to randomization. Trial names are defined in text.
ACS  acute coronary syndromes; NSTEMI  non–ST-segment elevation myocardial infarction.
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